Please assess the completion status of the following clinical trial:

Trial Title: RDEA3170 and Febuxostat Combination Study in Gout Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity.~* Meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.~* Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2.~* Screening serum urate level ≥ 8 mg/dL.~* Free of any clinically significant disease or medical condition, per the Investigator's judgment.~Exclusion Criteria:~* Unable to take colchicine for gout flare prophylaxis.~* History or suspicion of kidney stones.~* Any gastrointestinal disorder that affects motility and/or absorption.~* Unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.~* Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.~* Estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.~* Taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.~* Unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 10 mg (Type: EXPERIMENTAL): Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 15 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 5 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 2.5 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).